

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Burixafor Hydrobromide,GM CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Exicure Completes Enrollment for GPC-100 Phase 2 Myeloma Transplant Study
Details : GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, being investigated with propranolol and G-CSF in multiple myeloma patients undergoing autologous transplant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : Burixafor Hydrobromide,GM CSF,Propranolol Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
